News | Heart Failure | June 02, 2023

University College Dublin Researcher Receives ERC Funding to Unlock Insights Into Pig-to-human Heart Transplants

XenoSim project will establish the new field of ‘computational cardiac xenotransplantation’ and establish pioneering computational techniques with significant implications for a range of scientific disciplines

XenoSim project will establish the new field of ‘computational cardiac xenotransplantation’ and establish pioneering computational techniques with significant implications for a range of scientific disciplines

June 2, 2023 — Dr. Philip Cardiff, Associate Professor at University College Dublin's School of Mechanical and Materials Engineering, has received a European Research Council (ERC) Consolidator grant of €2 million for his 5-year project XenoSim. With the support of this award, Dr Cardiff will develop advanced computational techniques that can provide unprecedented insights into the cutting-edge realm of pig-to-human heart transplants

ERC Consolidator Grants are awarded to help excellent scientists, who have 7-12 years’ experience after their PhDs, to pursue their most promising ideas. Worth €657 million in total, the grants will create around 1950 jobs for postdoctoral fellows, PhD students, and other staff at host institutions around Europe 

President of the ERC Professor Maria Leptin said: “ERC Consolidator grants support researchers at a crucial time of their careers, strengthening their independence, reinforcing their teams and helping them establish themselves as leaders in their fields. And this backing above all gives them a chance to pursue their scientific dreams.” 

A funded investigator in the national Advanced Manufacturing Centre I-Form and Director of the Bekaert University Technology Centre at University College Dublin, Dr Cardiff said: “We stand on the threshold of a groundbreaking medical era where pig-to-human heart transplants are becoming a reality. From an engineering standpoint, pig hearts share similarities with their human counterparts in terms of ‘pump design’; however, their distinct size, shape, and functional characteristics introduce important differences that can impact their performance within the human body.” 

“With the support of this ERC Consolidator grant, we aim to unlock invaluable insights into these differences by developing advanced biomechanical computational models. This pioneering research promises to offer not only unprecedented insights into the cutting-edge realm of cardiac xenotransplantation but also to establish pioneering computational techniques with significant implications for a wide range of scientific disciplines.” 

The Project 

Xenotransplantation has long been a dream for clinicians and now, due to rapid progress in gene editing, is becoming a reality. To overcome immediate rejection, barriers of immunity and infection have to be overcome, but achieving long-term success requires a deep understanding of the physiological and mechanical challenges introduced by the anatomically dissimilar xenotransplants.  

‘XenoSim: Providing Computational Insights into Cardiac Xenotransplantation’, aims to address these challenges by providing fundamental clinical insights into the nascent field of cardiac xenotransplantation through the development and application of novel high-resolution, higher-order, multiphysics simulation methods. Tremendous progress has been made in biomedical imaging, nonetheless, a multitude of physical phenomena relevant to xenotransplantation are not available for experimental observation.  

In-silico studies are uniquely placed to provide insights into the haemodynamic disruption caused by replacing a human heart with an anatomically dissimilar one. XenoSim is targeting the establishment of the first family of porcine cardiac xenotransplant models that can provide clinically significant insights into the haemodynamic compatibility of porcine donor hearts, the impact of surgical approach, and the consequence of pathologies.  

To provide these novel insights requires new coupled simulation approaches. Accordingly, the project aims to create a new class of monolithic finite volume fluid-electrosolid interaction methods, which can provide predictions in clinically relevant timescales through the exploitation of hybrid CPU-GPU systems. XenoSim will establish the new field of computational cardiac xenotransplantation. Furthermore, the novel numerical methods established by XENOSIM are expected to impact a broad range of fields well beyond the project end. 

The XenoSim team will employ three Postdoctoral researchers, three PhD students and one Research Assistant. 

For more information: https://www.ucd.ie/research/portal/ 

Related Pig Heart Transplant News:   

Lab-grown Pig Heart Tissue Could Help Replace Live Animals in Heart Disease Research   

Pig Heart Transplant Patient Continues to Thrive   

First Human Receives a Pig Heart Transplant   

Transplanting Pig Hearts Into Humans One Step Closer   

FDA OKs Use New Version of Carmat Artificial Heart in U.S. Early Feasibility Study   

Carmat Artificial Heart Shows Promising Automatic Regulation of Blood Flow   

Heart in a Box Technology Expands Heart Transplant Window   

Abbott’s In-Development Fully Implantable Heart Pump System Earns FDA’s Breakthrough Device Designation   

FDA Clears SynCardia 50cc Temporary Total Artificial Heart as Bridge to Transplant   

Stephanie’s Heart: The Story of Baby Fae   

Hearts from donors who used illicit drugs or overdosed safe for transplant, cuts wait time   

National Trends in Heart Donor Utilization Rates: Are We Efficiently Transplanting More Hearts?   

Heart transplants from donors with hepatitis C may be safe and could help decrease organ shortage   

Find more cardiac surgery technology content   

Find more heart failure technology content  


Related Content

News | Heart Failure

April 16, 2024 — Each year more than 500,000 Americans undergo percutaneous coronary intervention, or PCI, a minimally ...

Home April 16, 2024
Home
News | Heart Failure

April 12, 2024 — University of Virginia School of Medicine researchers have discovered a gene on the Y chromosome that ...

Home April 12, 2024
Home
News | Heart Failure

April 2, 2024 — People who use e-cigarettes are significantly more likely to develop heart failure compared with those ...

Home April 02, 2024
Home
News | Heart Failure

March 29, 2024 — V-Wave announced it will present late-breaking data from its RELIEVE-HF pivotal trial at the American ...

Home March 29, 2024
Home
News | Heart Failure

March 25, 2024 — A team of engineers led by the University of Massachusetts Amherst and including colleagues from the ...

Home March 25, 2024
Home
News | Heart Failure

March 15, 2024 — BioCardia, Inc. , a biotechnology company focused on advancing late-stage cell therapy interventions ...

Home March 15, 2024
Home
News | Heart Failure

March 15, 2024 — BioCardia, Inc., a biotechnology company focused on advancing late-stage cell therapy interventions for ...

Home March 15, 2024
Home
News | Heart Failure

March 13, 2024 — BioCardia, Inc., a developer of cellular and cell-derived therapeutics for the treatment of ...

Home March 13, 2024
Home
News | Heart Failure

March 8, 2024 — The Texas Heart Institute, Georgia Institute of Technology (Georgia Tech), North Carolina State ...

Home March 08, 2024
Home
News | Heart Failure

March 5, 2024 — FIRE1 announced that it has completed patient enrollment in the U.S. Early Feasibility Study (FUTURE-HF2 ...

Home March 05, 2024
Home
Subscribe Now